Moody National Bank Trust Division Has $182,000 Stock Holdings in Neogen Co. (NASDAQ:NEOG)

Moody National Bank Trust Division grew its holdings in Neogen Co. (NASDAQ:NEOG) by 14.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,650 shares of the company’s stock after buying an additional 1,478 shares during the quarter. Moody National Bank Trust Division’s holdings in Neogen were worth $182,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Covestor Ltd raised its stake in shares of Neogen by 173.2% in the 1st quarter. Covestor Ltd now owns 1,970 shares of the company’s stock valued at $31,000 after buying an additional 1,249 shares in the last quarter. Connable Office Inc. acquired a new position in shares of Neogen in the 4th quarter valued at $202,000. Vise Technologies Inc. acquired a new position in shares of Neogen in the 4th quarter valued at $220,000. Bayesian Capital Management LP acquired a new position in shares of Neogen in the 1st quarter valued at $175,000. Finally, Inspire Advisors LLC acquired a new position in shares of Neogen in the 1st quarter valued at $176,000. Institutional investors and hedge funds own 96.73% of the company’s stock.

Neogen Price Performance

NASDAQ:NEOG traded up $0.60 during mid-day trading on Tuesday, reaching $16.75. 1,822,649 shares of the company were exchanged, compared to its average volume of 2,122,651. Neogen Co. has a 12 month low of $11.46 and a 12 month high of $24.09. The company has a fifty day moving average of $16.06 and a 200 day moving average of $15.22. The company has a quick ratio of 2.66, a current ratio of 3.82 and a debt-to-equity ratio of 0.28. The stock has a market cap of $3.63 billion, a PE ratio of 1,669.00 and a beta of 1.20.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings data on Tuesday, July 30th. The company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.02). Neogen had a positive return on equity of 3.09% and a negative net margin of 1.02%. The company had revenue of $236.80 million for the quarter, compared to the consensus estimate of $225.83 million. During the same period in the prior year, the company earned $0.14 EPS. The firm’s revenue was down 2.1% compared to the same quarter last year. On average, research analysts anticipate that Neogen Co. will post 0.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Piper Sandler increased their target price on shares of Neogen from $17.00 to $17.50 and gave the stock a “neutral” rating in a research report on Tuesday. StockNews.com upgraded shares of Neogen to a “sell” rating in a research report on Wednesday, July 10th.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.